McKesson Corporation

Valuation Analysis

About the Company

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution

McKesson Corporation Stock at a Glance

McKesson Corporation (MCK) is currently trading at $784.05 with a market capitalization of $94.2B. The trailing P/E ratio stands at 20.41x, with a forward P/E of 15.57x. The 52-week range spans from $637.00 to $999.00; the current price is 21.5% below the yearly high. Year-over-year revenue growth stands at +6.0%. The net profit margin stands at 1.18%.

💰 Dividend

McKesson Corporation pays an annual dividend of $3.28 per share, representing a yield of 0.42%. The payout ratio stands at 8.26%.

📊 Analyst Rating

15 analysts rate McKesson Corporation (MCK) on consensus: Strong Buy. The average price target is $941.40, implying +20.07% from the current price. Analyst price targets range from $812.00 to $1,065.00.

McKesson Corporation: The Investment Case in Detail

McKesson Corporation (MCK) operates in the Healthcare — specifically Medical Distribution — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 37.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Strong Buy with an average price target implying roughly 20.07% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

With a net margin of just 1.18%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.

What to Watch Next

• The forward P/E of 15.57x is meaningfully below the trailing 20.41x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 20.07% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy McKesson Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.